SEATTLE–(BUSINESS WIRE)–POSaBIT Systems Corporation (CSE: PBIT, OTC: POSAF), the leading provider of payments infrastructure in the cannabis industry, has announced “Cash Advance”, a new loan factoring program for the cannabis industry. The Cash Advance platform will allow POSaBIT’s payments merchants to secure a loan from the company quickly and without hassle, and subsequently repay the loan through payout deductions from the company’s in-store processing.
“We are very excited to unveil Cash Advance, which we see as a tremendous opportunity for any of our current partners to quickly access funds – and make their subsequent loan payments – with relative ease,” said Ryan Hamlin, founder/CEO of POSaBIT. “We know that retailers within the cannabis space are often in need of increased liquidity – whether that’s to purchase desirable product in bulk, break ground on renovations, scale their operations, or anything else. POSaBIT Cash Advance provides these retailers with both access to cash and a painless repayment program. We see it as a huge win all-around.”
POSaBIT Cash Advance will go live in Q4 with select beta accounts, with a planned full rollout in early 2022.
About POSaBIT
POSaBIT (CSE: PBIT) is a financial technology company that delivers unique and innovative blockchain-enabled payment processing and point-of-sale systems for cash-only businesses. POSaBIT specializes in resolving pain points for complex, high-risk, emerging industries like cannabis with an all-in-one solution that is compliant, user-friendly, and utilizes top- of-the-line hardware. POSaBIT’s unique solution provides a safe and transparent environment for merchants while creating a better overall experience for the consumer. For additional information, visit www.posabit.com.
Contacts
Investor Relations:
Media Relations:
Oscar Dahl
855-767-2248
[email protected]
Management:
Ryan Hamlin
Co-founder and CEO of POSaBIT
855-767-2248
[email protected]
Hayden IR
James Carbonara
(646) 755-7412
[email protected]
_(1).jpg "Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting"){kind=logo}
